Recurring Revenue Growth and Mix
Recurring revenue was $12.6M in Q1 2026, up $1.1M or 9% year-over-year, and represented ~94% of total revenue; management noted recurring revenue is annualizing over $50M, highlighting a more durable revenue base.
Installed Base Expansion
Placed 7 ALLY systems in the quarter bringing ALLY installed base to ~205 systems (ALLY now ~half of global installed base); total installed base of ALLY and LLS reached ~440 systems, up 12% versus March 31, 2025; backlog included ~11 systems pending installation.
Procedure Volume and Market Share
Performed ~54,000 procedures in Q1 2026 versus ~52,000 in Q1 2025 (and 39,000 in 2024); U.S. procedure market share was 23.4%, consistent with the prior quarter.
Commercial Momentum Post-Transaction
Post-merger termination activity showed encouraging signs: distributor purchase orders were received after quarter-end, management expects to ship systems outside the U.S. this quarter (first time in ~1 year), >50 system demos at ASCRS and ~77 participants on a users Webex demonstrating renewed surgeon/distributor engagement.
Reported Operating Expense Reduction (Transaction-Related)
Total operating expenses declined to $4.1M from $12.9M year-over-year, with reported SG&A down to $2.5M from $11.1M primarily due to a $4.4M credit and elimination of acquisition-related costs; when excluding acquisition-related charges, SG&A was stable at $6.9M year-over-year.
Strategic Product Roadmap and Management Focus
Management emphasized a clear go-forward strategy to rebuild placements and grow recurring revenue, and outlined R&D priorities including additional corneal applications, increased robotic functionality and docking automation for the ALLY platform — positioning for continued technological leadership.